Mutual of America Capital Management LLC Sells 1,598 Shares of Catalyst Pharmaceuticals, Inc. $CPRX

Mutual of America Capital Management LLC decreased its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 9.8% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 14,729 shares of the biopharmaceutical company’s stock after selling 1,598 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Catalyst Pharmaceuticals were worth $320,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of CPRX. GAMMA Investing LLC increased its stake in shares of Catalyst Pharmaceuticals by 26.2% in the 1st quarter. GAMMA Investing LLC now owns 2,791 shares of the biopharmaceutical company’s stock worth $68,000 after acquiring an additional 579 shares in the last quarter. PNC Financial Services Group Inc. increased its stake in shares of Catalyst Pharmaceuticals by 57.2% during the first quarter. PNC Financial Services Group Inc. now owns 5,501 shares of the biopharmaceutical company’s stock valued at $133,000 after purchasing an additional 2,002 shares in the last quarter. US Bancorp DE increased its stake in shares of Catalyst Pharmaceuticals by 17.8% during the first quarter. US Bancorp DE now owns 7,328 shares of the biopharmaceutical company’s stock valued at $178,000 after purchasing an additional 1,105 shares in the last quarter. Headlands Technologies LLC bought a new position in shares of Catalyst Pharmaceuticals during the first quarter valued at approximately $188,000. Finally, Quarry LP increased its stake in shares of Catalyst Pharmaceuticals by 60.0% during the first quarter. Quarry LP now owns 8,000 shares of the biopharmaceutical company’s stock valued at $194,000 after purchasing an additional 3,000 shares in the last quarter. 79.22% of the stock is currently owned by institutional investors.

Catalyst Pharmaceuticals Trading Down 1.6%

Catalyst Pharmaceuticals stock opened at $21.01 on Thursday. The firm has a market cap of $2.57 billion, a price-to-earnings ratio of 12.73, a PEG ratio of 0.85 and a beta of 0.79. The stock has a fifty day simple moving average of $20.39 and a two-hundred day simple moving average of $21.85. Catalyst Pharmaceuticals, Inc. has a 12 month low of $19.05 and a 12 month high of $26.58.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last released its quarterly earnings data on Monday, September 25th. The biopharmaceutical company reported $0.28 EPS for the quarter. Catalyst Pharmaceuticals had a return on equity of 40.78% and a net margin of 37.36%.The company had revenue of $53.11 million during the quarter. On average, equities research analysts forecast that Catalyst Pharmaceuticals, Inc. will post 1.9 EPS for the current fiscal year.

Catalyst Pharmaceuticals announced that its board has approved a share repurchase program on Wednesday, October 1st that authorizes the company to repurchase $200.00 million in shares. This repurchase authorization authorizes the biopharmaceutical company to buy up to 8.3% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s management believes its stock is undervalued.

Insider Activity at Catalyst Pharmaceuticals

In other news, insider Brian Elsbernd sold 30,000 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $20.30, for a total value of $609,000.00. Following the completion of the sale, the insider directly owned 271,039 shares in the company, valued at $5,502,091.70. The trade was a 9.97% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Richard J. Daly sold 22,970 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Tuesday, August 26th. The stock was sold at an average price of $20.62, for a total transaction of $473,641.40. Following the completion of the sale, the chief executive officer directly owned 226,794 shares of the company’s stock, valued at approximately $4,676,492.28. This trade represents a 9.20% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 243,970 shares of company stock valued at $4,927,241. Insiders own 10.40% of the company’s stock.

Wall Street Analyst Weigh In

CPRX has been the subject of a number of analyst reports. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Catalyst Pharmaceuticals in a research report on Wednesday, October 8th. Zacks Research lowered Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 19th. Finally, Wall Street Zen upgraded Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Sunday, October 12th. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $33.20.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.